Harbour BioMed’s HBM7004 China IND acceptance sharpens the race for B7-H4 cancer targets
Find out how Harbour BioMed’s HBM7004 China IND acceptance could reshape B7-H4 solid tumor immunotherapy development.
HBM7004 FDA clearance gives Harbour BioMed a fresh solid tumor immunotherapy test
Solid tumor T-cell engagers still face safety limits. Harbour BioMed’s HBM7004 now tests whether B7-H4 can widen that window.